{
  "study_id": "NCT05351541",
  "agent": "baseline",
  "run": 2,
  "p_primary_hypothesis_supported": 0.83,
  "effect_direction": "favours intervention",
  "effect_size_90pct_interval": {"low": 3, "high": 20, "metric": "Mean change in BPI interference, 0-70 scale, baseline to 1 month (positive = reduction)"},
  "moderator_prediction": "none detectable; n~30 split over four add-on arms leaves roughly 7 per arm, far too few to show differences. If anything, zolpidem-containing arms may show slightly smaller reductions if sedation blunts the acute psychedelic experience.",
  "claim_ids_used": [],
  "rationale": "Every participant gets open psilocybin plus therapy, so the pooled primary is effectively a single-arm pre-post test on a self-reported outcome, where significant improvement is very likely (primer 1.6, Step 2: often >90%) due to regression to the mean, expectancy and functional unblinding. Treatment-refractory CLBP baseline BPI interference is likely ~30-40/70; a 1-month reduction of ~8-12 points is plausible. Discounts: small n (~30, with dropout), chronic-pain outcomes respond less to expectancy, dose range 1-30 mg may include sub-therapeutic doses, and zolpidem add-on may blunt effects, widening variance. Also slight risk the report emphasises between-arm comparisons or is underpowered pooled."
}